AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ™) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis - PRNewswire Get link Facebook X Pinterest Email Other Apps October 18, 2019 AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ™) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis PRNewswire Get link Facebook X Pinterest Email Other Apps Comments
Comments
Post a Comment